Skip to main content

Table 1 Patients’ characteristics at baseline

From: Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study)

 

Pitavastatin (n = 10)

Pravastatin (n = 10)

p value

Age, year

68 ± 5

64 ± 11

0.26

Man, n (%)

7 (70)

8 (80)

>0.99

Height, cm

161.3 ± 6.1

162.5 ± 11.3

0.78

Body weight, kg

65.0 ± 9.1

63.5 ± 10.6

0.73

Main history, n (%)

   

Hypertension

5 (50)

5 (50)

>0.99

Diabetes mellitus

4 (40)

2 (20)

0.36

Smoking, n (%)

6 (60)

5 (50)

0.67

Valvular heart disease

3 (30)

2 (20)

0.63

Medications, n (%)

   

ARBs or ACEIs

2 (20)

5 (50)

0.18

Beta-blockers

3 (30)

3 (30)

>0.99

Ca channel blockers

4 (40)

3 (30)

0.67

  1. ARBs: angiotensin II receptor blockers, ACEIs: angiotensin-converting enzyme inhibitors, Ca: calcium.